Previous 10 | Next 10 |
Priority Health, a nationally recognized nonprofit health plan, announced today the launch of PriorityGPS™, an integrated health navigation and advocacy solution. PriorityGPS will be delivered through a strategic partnership with Accolade (Nasdaq: ACCD), a Personalized Healthcare...
ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...
Image source: The Motley Fool. Accolade, Inc. (NASDAQ: ACCD) Q1 2023 Earnings Call Jun 30, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Accolade, Inc. (ACCD) Q1 2023 Earnings Call Transcript
Meta ( NASDAQ: META ) represented one of the biggest name stocks seeing a midday move on Friday. Shares of the Facebook parent edged lower as it cut back on its hiring plans in the face of a cautious economic forecast. Meanwhile, PureCycle ( PCT ) also made the list of midda...
Gainers: Allena Pharmaceuticals ( ALNA ) +46% . Mega Matrix ( MTMT ) +43% . Faraday Future Intelligent Electric ( FFIE ) +30% . Tyra Biosciences ( TYRA ) +29% . Omeros ( OMER ) +28% . Clovis Oncology ( CLVS ) +22% . ...
Gainers: Accolade ( ACCD ) +18% . Clovis Oncology ( CLVS ) +18% . Larimar Therapeutics ( LRMR ) +14% . Tyra Biosciences ( TYRA ) +13% . VectivBio Holding ( VECT ) +13% . Losers: Talaris Therapeutics ( TALS ) -48% . Agile Therapeu...
The following slide deck was published by Accolade, Inc. in conjunction with their 2023 Q1 earnings call. For further details see: Accolade, Inc. 2023 Q1 - Results - Earnings Call Presentation
Accolade, Inc. (ACCD) Q1 2023 Earnings Conference Call June 30, 2022 04:30 p.m. ET Company Representatives Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior Vice Preside...
Accolade press release ( NASDAQ: ACCD ): Q1 GAAP EPS of -$4.92 misses by $4.18 . Revenue of $85.5M (+43.7% Y/Y) beats by $3.53M . Revenue between $82 million and $83.5 million for the fiscal second quarter ending August 31, 2022. Adjusted EBITDA between $(1...
Fiscal first quarter 2023 revenue of $85.5 million, a 44% increase compared to fiscal first quarter 2022 revenue of $59.5 million SEATTLE, June 30, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 50.0% to $0.495 on volume of 360,218,139 shares NVIDIA Corporation (NVDA) fell 0.4% to $123.54 on volume of 307,578,749 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) rose 8.1% to $0.3343 on vol...